BioDelivery Sciences International Inc. (NASDAQ:BDSI)‘s stock had its “buy” rating reaffirmed by analysts at FBR & Co in a research note issued on Tuesday.

A number of other equities analysts have also recently commented on BDSI. Cantor Fitzgerald reaffirmed a “hold” rating on shares of BioDelivery Sciences International in a research note on Saturday, July 9th. Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Wednesday, July 27th. Janney Montgomery Scott reaffirmed a “hold” rating and issued a $4.00 price target on shares of BioDelivery Sciences International in a research note on Tuesday, July 12th. Finally, Piper Jaffray Cos. reaffirmed a “sell” rating and issued a $4.00 price target on shares of BioDelivery Sciences International in a research note on Wednesday, August 10th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $7.00.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded down 2.05% during trading on Tuesday, reaching $2.39. The company’s stock had a trading volume of 682,772 shares. The stock’s 50 day moving average is $2.55 and its 200 day moving average is $2.71. The firm’s market cap is $128.20 million. BioDelivery Sciences International has a one year low of $1.86 and a one year high of $7.04.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/biodelivery-sciences-international-inc-bdsi-receives-buy-rating-from-fbr-co-2.html

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.31). The business had revenue of $5 million for the quarter, compared to analysts’ expectations of $3.35 million. BioDelivery Sciences International had a negative return on equity of 233.80% and a negative net margin of 109.64%. The business’s quarterly revenue was up 194.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.37) EPS. On average, equities analysts forecast that BioDelivery Sciences International will post ($1.14) EPS for the current fiscal year.

In related news, Director William B. Stone sold 16,000 shares of the company’s stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $2.57, for a total value of $41,120.00. Following the sale, the director now directly owns 122,675 shares of the company’s stock, valued at $315,274.75. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 9.00% of the company’s stock.

A number of large investors have recently modified their holdings of BDSI. Metropolitan Life Insurance Co. NY boosted its stake in shares of BioDelivery Sciences International by 1.8% in the first quarter. Metropolitan Life Insurance Co. NY now owns 32,132 shares of the specialty pharmaceutical company’s stock valued at $104,000 after buying an additional 581 shares during the last quarter. Squarepoint Ops LLC boosted its stake in shares of BioDelivery Sciences International by 22.1% in the first quarter. Squarepoint Ops LLC now owns 41,400 shares of the specialty pharmaceutical company’s stock valued at $134,000 after buying an additional 7,500 shares during the last quarter. Alpine Partners VI LLC purchased a new stake in shares of BioDelivery Sciences International during the second quarter valued at $147,000. Krilogy Financial LLC purchased a new stake in shares of BioDelivery Sciences International during the second quarter valued at $164,000. Finally, Menta Capital LLC purchased a new stake in shares of BioDelivery Sciences International during the second quarter valued at $224,000. 60.12% of the stock is currently owned by institutional investors.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.